rs6901953
Variant summary
Our verdict is Benign. Variant got -19 ACMG points: 0P and 19B. BP4_ModerateBP6_Very_StrongBP7BA1
The NM_006073.4(TRDN):āc.1188A>Gā(p.Lys396Lys) variant causes a splice region, synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.354 in 1,470,594 control chromosomes in the GnomAD database, including 95,898 homozygotes. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Benign (ā ā ).
Frequency
Consequence
NM_006073.4 splice_region, synonymous
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -19 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TRDN | NM_006073.4 | c.1188A>G | p.Lys396Lys | splice_region_variant, synonymous_variant | 17/41 | ENST00000334268.9 | NP_006064.2 | |
TRDN | NM_001251987.2 | c.1191A>G | p.Lys397Lys | splice_region_variant, synonymous_variant | 17/21 | NP_001238916.1 | ||
TRDN | NM_001407315.1 | c.1131A>G | p.Lys377Lys | splice_region_variant, synonymous_variant | 16/20 | NP_001394244.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TRDN | ENST00000334268.9 | c.1188A>G | p.Lys396Lys | splice_region_variant, synonymous_variant | 17/41 | 1 | NM_006073.4 | ENSP00000333984.5 | ||
TRDN | ENST00000662930.1 | c.1191A>G | p.Lys397Lys | splice_region_variant, synonymous_variant | 17/21 | ENSP00000499585.1 |
Frequencies
GnomAD3 genomes AF: 0.346 AC: 52611AN: 151980Hom.: 9526 Cov.: 32
GnomAD3 exomes AF: 0.333 AC: 52080AN: 156336Hom.: 9330 AF XY: 0.323 AC XY: 26813AN XY: 82984
GnomAD4 exome AF: 0.355 AC: 467949AN: 1318496Hom.: 86355 Cov.: 24 AF XY: 0.349 AC XY: 228237AN XY: 654760
GnomAD4 genome AF: 0.346 AC: 52661AN: 152098Hom.: 9543 Cov.: 32 AF XY: 0.336 AC XY: 24970AN XY: 74330
ClinVar
Submissions by phenotype
not specified Benign:6
Benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Nov 24, 2014 | Lys396Lys in exon 17 of TRDN: This variant is not expected to have clinical sign ificance because it does not alter an amino acid residue and is not located with in the splice consensus sequence. It has been identified in 36.4% (2890/7950) of European American chromosomes from a broad population by the NHLBI Exome Sequen cing Project (http://evs.gs.washington.edu/EVS; dbSNP rs6901953). - |
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 04, 2023 | - - |
Benign, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Sep 27, 2016 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Benign, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | - | - - |
Catecholaminergic polymorphic ventricular tachycardia 1 Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Cardiovascular phenotype Benign:1
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 09, 2015 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Catecholaminergic polymorphic ventricular tachycardia 5 Benign:1
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Sep 10, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at